Synchronous primary neoplasia in patients with oropharyngeal cancer: Impact of tumor HPV status. A GETTEC multicentric study.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
01 2021
Historique:
received: 28 07 2020
revised: 28 09 2020
accepted: 04 10 2020
pubmed: 1 11 2020
medline: 23 9 2021
entrez: 31 10 2020
Statut: ppublish

Résumé

Patients with oropharyngeal squamous cell carcinoma (OPSCC) display a significant risk of synchronous primary neoplasia (SPN) which could impact their management. The aims of this study were to evaluate the risk and distribution of SPN in OPSCC patients according to their HPV (p16) status, the predictive factors of SPN and the impact of SPN on therapeutic strategy and oncologic outcomes. All OPSCC patients treated from 2009 to 2014 were included in this multicentric retrospective study. Univariate analyses were conducted using Chi-2 and Fisher exact tests. For multivariate analyses, all variables associated with a p ≤ 0.10 in univariate analysis were included in logistic regression models. Among the 1291 patients included in this study, 75 (5.8%) displayed a SPN which was preferentially located in the upper aerodigestive tract, lung and esophagus. Comorbidity level (p = 0.03), alcohol (p = 0.005) and tobacco (p = 0.01) consumptions, and p16 tumor status (p < 0.0001) were significant predictors of SPN. In multivariate analysis, p16+ status was significantly associated with a lower risk of SPN (OR = 0.251, IC95% [0.133;0.474]). Patients with a SPN were more frequently referred for non-curative treatment (p = 0.02). In patients treated with curative intent, there was no impact of SPN on the therapeutic strategy (surgical vs. non-surgical treatment). We observed no overall survival differences between patients with or without SPN. P16 tumor status is the main predictive factor of SPN in OPSCC patients. This study provides crucial results which should help adapt the initial work-up and the global management of OPSCC patients.

Identifiants

pubmed: 33129057
pii: S1368-8375(20)30477-2
doi: 10.1016/j.oraloncology.2020.105041
pii:
doi:

Substances chimiques

Cyclin-Dependent Kinase Inhibitor p16 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

105041

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Florent Milliet (F)

Department of Otorhinolaryngology, University Hospital of Nice, France.

Alexandre Bozec (A)

University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Renaud Schiappa (R)

Department of Statistics, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Julien Viotti (J)

Department of Statistics, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Anouchka Modesto (A)

Department of Radiotherapy, Cancer University Institute of Toulouse, Toulouse, France.

Olivier Dassonville (O)

University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Gilles Poissonnet (G)

University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Bruno Guelfucci (B)

Department of Otorhinolaryngology and Head and Neck Surgery, Sainte Musse Hospital, Toulon, France.

Alain Bizeau (A)

Department of Otorhinolaryngology and Head and Neck Surgery, Sainte Musse Hospital, Toulon, France.

Sebastien Vergez (S)

Department of Otorhinolaryngology and Head and Neck Surgery, Cancer University Institute of Toulouse, Toulouse, France.

Agnes Dupret-Bories (A)

Department of Otorhinolaryngology and Head and Neck Surgery, Cancer University Institute of Toulouse, Toulouse, France.

Renaud Garrel (R)

Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Montpellier, Montpellier, France.

Nicolas Fakhry (N)

Department of Otorhinolaryngology and Head and Neck Surgery, Public Assistance - Hospitals of Marseille, Marseille, France.

Laure Santini (L)

Department of Otorhinolaryngology and Head and Neck Surgery, Public Assistance - Hospitals of Marseille, Marseille, France.

Benjamin Lallemant (B)

Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Nîmes, Nîmes, France.

Guillaume Chambon (G)

Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Nîmes, Nîmes, France.

Anne Sudaka (A)

Department of Pathology, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Frederic Peyrade (F)

Department of Medical Oncology, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Esma Saada-Bouzid (E)

Department of Medical Oncology, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Karen Benezery (K)

Department of Radiotherapy, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Florence Jourdan-Soulier (F)

Department of Pathology, Sainte Musse Hospital, Toulon, France.

Françoise Chapel (F)

Department of Pathology, Sainte Musse Hospital, Toulon, France.

Anne Sophie Ramay (A)

Department of Pathology, University Hospital of Nîmes, Nîmes, France.

Pascal Roger (P)

Department of Pathology, University Hospital of Nîmes, Nîmes, France.

Thibault Galissier (T)

Department of Pathology, Cancer University Institute of Toulouse, Toulouse, France.

Valérie Coste (V)

Department of Pathology, University Hospital of Montpellier, Montpellier, France.

Aicha Ben Lakdar (A)

Department of Pathology, Gustave Roussy Institute, Villejuif, France.

Joanne Guerlain (J)

Department of Otorhinolaryngology and Head and Neck Surgery, Gustave Roussy Institute, Villejuif, France.

Stephane Temam (S)

Department of Otorhinolaryngology and Head and Neck Surgery, Gustave Roussy Institute, Villejuif, France.

Haitham Mirghani (H)

Department of Head and Neck Surgery, European Georges Pompidou Hospital, APHP, Paris, France.

Phillipe Gorphe (P)

Department of Otorhinolaryngology and Head and Neck Surgery, Gustave Roussy Institute, Villejuif, France.

Emmanuel Chamorey (E)

Department of Statistics, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Dorian Culié (D)

University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France. Electronic address: dorian.culie@nice.unicancer.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH